Endonovo Therapeutics, Inc.
ENDV
Other OTC0.00
USD
- -
- -
CIK
0001528172
ISIN
US29272H3003
CUSIP
29272H300
Return %
Stock
S&P500
1Y
- -
26.84
3Y
-99.21
77.03
5Y
-99.67
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Alan Brian Collier
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 6320 Canoga Avenue Woodland Hills CA United States of America 91367
- IPO Date
- Nov 15, 2012
- CIK
- 0001528172
- Website
- endonovo.com
- Similar Companies
- Business
- Endonovo Therapeutics, Inc. (OTCQB: ENDV) develops, manufactures and commercializes non-invasive wearable Electroceutical medical devices that deliver proprietary pulsed electromagnetic field (PEMF) therapy using pulsed radio-frequency waves at 27.12 MHz to accelerate endogenous nitric oxide production for anti-inflammatory effects; its flagship SofPulse platform treats chronic wounds, post-surgical pain and edema (FDA-cleared with CMS national coverage), soft tissue injuries and inflammatory conditions, while its clinical pipeline targets cardiovascular diseases including ischemic heart disease and peripheral artery disease, as well as central nervous system disorders such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke and multiple sclerosis; the therapy is also CE marked for wound healing and edema reduction. Founded in 2008 and headquartered in Woodland Hills, California, the company operates primarily in the United States with international distribution efforts in Asia (Taiwan, Singapore, South Korea, Thailand, Hong Kong), Mexico, Central and South America, and Europe. In March 2024, Endonovo closed a major asset purchase agreement with SofPulse, Inc. for a minimum of $50 million (potentially up to $100 million pending third-party valuation) involving the sale of its human medical PEMF intellectual property and FDA clearances, enabling a strategic pivot to non-medical human PEMF wellness products, multi-coil over-the-counter devices, telehealth platforms (via exclusive five-year customer agreement), and mergers/acquisitions for complementary technologies; the transaction positions SofPulse, Inc. to expand SofPulse distribution into VA/DoD markets, U.S. hospitals, rehabilitation facilities and additional Asian/Latin American regions.
Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc
Endonovo's SofPulse® to Be Featured at Innovative Pain Management Solutions
Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million
Endonovo's SofPulse® Secures Taiwan FDA Approval
Endonovo's SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution
Endonovo's Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update